OSTX today
$0.79-$0.08 (-9.20%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $2.02
Key levels
Resistance$1.33
Resistance$1.16
Latest news & SEC filings
LegalOS Therapies seeks U.K. approval path for Herlystic
ProductOS Therapies finishes quality check for Phase 2b Herlystic ingredient
ProductOS Therapies clears Herlystic material for confirmatory late-stage study
All OSTX news →About OS Therapies
OS Therapies develops medicines for bone cancers and other solid tumors, working mainly on osteosarcoma, which affects children and young adults. Its main candidate, OST-HER2, is an immunotherapy that prompts the body's immune system to attack the HER2 cancer antigen, and it has been tested in patients whose recurrent osteosarcoma was surgically removed. The company also holds a preclinical antibody-drug conjugate technology called OST-tADC. It carries out development in the United States and seeks approvals in the U.S., U.K. and Europe.
Based on the company's 10-K filed Mar 31, 2026.
NYSE · Healthcare
OS Therapies Inc (OSTX)
What Is the Price Target for OSTX?
SEPT Low Target
$7.00
SEPT Mid Target
$7.00
SEPT High Target
$7.00
Analyst Consensus
$7.00
Is OSTX a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for OSTX.
Start Free Trial →Is OSTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$7.00
17
Moat Score
NONE
1/9
Piotroski Score
-27.9
Altman Z-Score
What Is Smart Money Doing with OSTX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →OSTX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
23.44%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for OSTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for OSTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:26:03 | $0.77 | 2,000 | $$2K | BUY |
| 16:25:14 | $0.76 | 1,620 | $$1K | BUY |
| 16:18:46 | $0.77 | 5,000 | $$4K | MIDPOINT |
| 16:12:07 | $0.78 | 1,300 | $$1K | SELL |
| 16:08:57 | $0.79 | 1,000 | $$785 | SELL |
5 dark pool trades shown · $$8K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for OS Therapies Inc (OSTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (27 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →OSTX — frequently asked questions
What is OSTX stock price today?
OS Therapies Inc (OSTX) is at $0.79, down 9.20% (-$0.08) at the Nov 12, 2026 close.
Why is OSTX stock moving today?
Latest OSTX news — Nov 11, 2026: OS Therapies seeks U.K. approval path for Herlystic · Nov 5, 2026: OS Therapies finishes quality check for Phase 2b Herlystic ingredient
What is the OSTX price target?
The average analyst price target for OSTX is $7.00, ranging from $7 to $7, based on 2 analysts. Latest: Roth Capital initiates on Jul 9, 2026.
What do analysts rate OSTX?
Analyst ratings for OSTX: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did OSTX beat earnings?
OSTX last reported on Aug 17, 2026: EPS -$0.20 vs -$0.18 expected — a miss of 12.4%.
Does OSTX pay a dividend?
Yes. OSTX's dividend yield is 34.99%.
What are OSTX support and resistance levels?
Resistance: $1.16, $1.33, $1.46.
What are insiders doing with OSTX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on OSTX?
Nov 11, 2026: OS Therapies seeks U.K. approval path for Herlystic · Nov 5, 2026: OS Therapies finishes quality check for Phase 2b Herlystic ingredient · Nov 5, 2026: OS Therapies clears Herlystic material for confirmatory late-stage study